Supplementary Fig. S4 from Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression

Azusa Tanimoto,Shingo Matsumoto,Shinji Takeuchi, Soichi Arai,Koji Fukuda,Akihiro Nishiyama,Kiyotaka Yoh,Takaya Ikeda,Naoki Furuya,Kazumi Nishino,Yuichiro Ohe,Kōichi Goto,Seiji Yano

openalex（2023）

引用 0|浏览7

暂无评分

摘要

Kaplan-Meier curves for PFS according to ATM mutation status in patients who received alectinib (A) or either of ALK-TKIs (alectinib, crizotinib, brigatinib, lorlatinib, ceritinib) (B) as the first TKI treatment.

查看译文

关键词

proteasome,nsclc,alk-tki

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要